SEARCH

SEARCH BY CITATION

References

  • 1
    McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1981; 304:11351147.
  • 2
    Malinowska I, Obitko-Płudowska A, Buescher ES, Wasik M, Rokicka-Milewska R. Release of cytokines and soluble cytokine receptors after intravenous anti-D treatment in children with chronic thrombocytopenic purpura. Hematol J 2001; 2:242249.
  • 3
    Provan D, Stasi R, Newland AC et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168186.
  • 4
    Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000; 160:16301638.
  • 5
    Michel M. Immune thrombocytopenic purpura. Epidemiology and implications for patients. Eur J Haematol Suppl 2009; 71:37.
  • 6
    Zahran AM, Elsayh KI. CD4+CD25+High Foxp3+ regulatory T cells, B lymphocytes, and T lymphocytes in patients with acute ITP in Assiut Children's Hospital. Clin Appl Thromb Hemost 2012; 0:17.
  • 7
    Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura. Current concepts in pathophysiology and management. Thromb Haemost 2008; 99:413.
  • 8
    Coopamah MD, Garvey MB, Freedman J, Semple JW. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. Transfus Med Rev 2003; 17:6980.
  • 9
    Zhang F, Chu X, Wang L et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2006; 76:427431.
  • 10
    Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113:65116521.
  • 11
    Ogawara H, Handa H, Morita K et al. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2003; 71:283288.
  • 12
    Kuwana M, Kaburaki J, Kitasato H et al. Immunodominant epitopes on glycoprotein IIb–IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood 2001; 98:130139.
  • 13
    Culic S, Labar B, Marusic A, Salamunic I. Correlations among age, cytokines, lymphocyte subtypes, and platelet counts in autoimmune thrombocytopenic purpura. Pediatr Blood Cancer 2006; 47:671674.
  • 14
    Erduran E, Asian Y, Aliyazicioglu Y, Mocan H, Gedik Y. Plasma soluble interleukin 2 receptor levels in patients with idiopathic thrombocytopenic purpura. Am J Hematol 1998; 57:119123.
  • 15
    Andersson PO, Stockelberg D, Jacobsson S, Wadenvik H. A transforming growth factor-B1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol 2000; 79:507513.
  • 16
    Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010; 11:713.
  • 17
    Sakaguchi S. Naturally arising Foxp3-expressing CD25?CD4? regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6:345352.
  • 18
    Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133:775787.
  • 19
    Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 2003; 171:63236327.
  • 20
    Korn T, Oukka M. Dynamics of antigen-specific regulatory T-cells in the context of autoimmunity. Semin Immunol 2007; 19:272278.
  • 21
    Thompson C, Powrie F. Regulatory T cells. Curr Opin Pharmacol 2004; 4:408414.
  • 22
    Valencia X, Lipsky PE. CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol 2007; 3:619626.
  • 23
    Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol 2007; 79:310316.
  • 24
    Sakakura M, Wada H, Tawara I et al. Reduced CD4+CD25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 2007; 120:187193.
  • 25
    Lanzkowsky P. Disorders of platelets. In: Lanzkowsky P , ed. Manual of Pediatric Hematology and Oncology. New York: Academic Press, 2004:250294.
  • 26
    Torubarova NA, Koshe IV, Mambetova N. Effect of glucocorticoids therapy on membrane markers of lymphocytes and monocytes in children with chronic ITP. Gematol Transfuziol 1989; 84:713.
  • 27
    Talaat RM, El-Bassiouny AI, Osman AM, Yossif M, Charmy R, Al-Sherbiny MM. Cytokine secretion profile associated with periportal fibrosis in S. mansoni-infected Egyptian patients. Parasitol Res 2007; 101:289299.
  • 28
    Fahim NM, Monir E. Functional role of CD4+CD25+ regulatory T cells and transforming growth factor-beta1 in childhood immune thrombocytopenic purpura. Egypt J Immunol 2006; 13:173187.
  • 29
    Danato H, Picon A, Robetti MC, Schvarrtzman G, Varela DM, Galvagni A. Evaluation of prognostic factors in childhood idiopathic thrombocytopenic purpura. Br J Haematol 1998; 102:321326.
  • 30
    Edslev PW, Rosthoj S, Treutiger I et al. A clinical score predicting a brief and uneventful course of newly diagnosed idiopathic thrombocytopenic purpura in children. Br J Haematol 2007; 138:513516.
  • 31
    Ahmed S, Siddiqui AK, Shahid RK, Kimpo M, Sison CP, Hoffman MA. Prognostic variables in newly diagnosed childhood immune thrombocytopenia. Am J Hematol 2004; 77:358362.
  • 32
    McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol 2007; 44 (4 Suppl. 5):S311.
  • 33
    Chen JF, Yang LH, Dong CX et al. Significance of detection of anti-GPIIb/IIIa antibody secreting B cells and platelet-specific antibody in patients with idiopathic thrombocytopenic purpura. Zhonghua Xue Ye Xue Za Zhi 2010; 31:603606.
  • 34
    Chen JF, Yang LH, Feng JJ, Chang LX, Liu XE, Lu YJ. The clinical significance of immune-related marker detection in idiopathic thrombocytopenic purpura. Zhonghua Nei Ke Za Zhi 2010; 49:5768.
  • 35
    Kuwana M, Okazaki Y, Satoh T, Asahi A, Kajihara M, Ikeda Y. Initial laboratory findings useful for predicting the diagnosis of idiopathic thrombocytopenic purpura. Am J Med 2005; 118:10261033.
  • 36
    French AR, Yokoyama WM. Natural killer cells and autoimmunity. Arthritis Res Ther 2004; 6:814.
  • 37
    O'Gorman M, Smith R, Garrison A, Shamiyeh E, Pachman L. Lymphocyte subsets in peripheral blood from newly diagnosed, untreated patients with juvenile dermatomyositis (JDM) are associated with disease activity scores (DAS). Arthritis Rheum 2002; 46 (Suppl. 9):S490.
  • 38
    Yabuhara A, Yang FC, Nakazawa T et al. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol 1996; 23:171177.
  • 39
    Riccieri V, Spadaro A, Parisi G et al. Down-regulation of natural killer cells and of gamma/delta T cells in systemic lupus erythematosus. Does it correlate to autoimmunity and to laboratory indices of disease activity? Lupus 2000; 9:333337.
  • 40
    Takahashi K, Miyake S, Kondo T et al. Natural killer type 2 bias in remission of multiple sclerosis. J Clin Invest 2001; 107:2329.
  • 41
    James K, Ritchie AWS. Do natural killer cells regulate B cell activity? Immunol Today 1984; 5:193194.
  • 42
    Semple JW, Bruce S, Freedman J. Suppressed natural killer cell activity in patients with chronic autoimmune thrombocytopenic purpura. Am J Hematol 1991; 37:258262.
  • 43
    Iwatani Y, Amino N, Mori H et al. T lymphocyte subsets in autoimmune thyroid diseases and subacute thyroiditis detected with monoclonal antibodies. J Clin Endocrinol Metab 1983; 56:251254.
  • 44
    Bonnyns M, Bentin J, Devetter G, Duchateau J. Heterogeneity of immunoregulatory T cells in human thyroid autoimmunity: influence of thyroid status. Clin Exp Immunol 1983; 52:629634.
  • 45
    Thielemans C, Vanhaelst L, de Waele M, Jonckheer M, Van Camp B. Autoimmune thyroiditis: a condition related to a decrease in T-suppressor cells. Clin Endocrinol 1981; 15:259263.
  • 46
    Berrih S, Gaud C, Bach MA, Brigand HL, Binet JP, Bach JF. Evaluation of T cell subsets in myasthenia gravis using anti-T cell monoclonal antibodies. Clin Exp Immunol 1981; 45:18. 48.
  • 47
    Kreuzfelder E, Shen G, Bittorf M et al. Enumeration of T, B and natural killer peripheral blood cells of patients with multiple sclerosis and controls. Eur Neurol 1992; 32:190194.
  • 48
    Fox RI, Fong S, Sabharwal N, Carstens SA, Kung PC, Vaughan JH. Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis. J Immunol 1982; 128:351354.
  • 49
    Moreno-Otero R, Civeira MP, Suou T, Kanof ME, James SP, Jones EA. Reduced numbers of CD8+ T cells and B cell expression of Leu-8 antigen in peripheral blood of patients with primary biliary cirrhosis. Hepatogastroenterology 1994; 41:239243.
  • 50
    Booss J, Esiri MM, Tourtellotte WW, Mason DY. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci 1983; 62:219232.
  • 51
    Robak E, Blonski JZ, Bartkowiak J, Niewiadomska H, Sysa-Jçcedrzejowska A, Robak T. Circulating TCR γδ cells in patients with systemic lupus erythematosus. Mediat Inflamm 1999; 8:305312.
  • 52
    Rosmalen JGM, van Ewijk W, Leenen PJM. T-cell education in autoimmune diabetes: teachers and students. Trends Immunol 2002; 23:4046.
  • 53
    von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005; 6:338344.
  • 54
    Bacchetta R, Gambineri E, Roncarolo MG. Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol 2007; 120:227235.
  • 55
    Grossley AR, Dickinson AM, Proctor SJ, Calvert JE. Effects of interferon-alpha therapy on immune parameters in immune thrombocytopenic purpura. Autoimmunity 1993; 24:81100.
  • 56
    Haznedaroglu IC, Sayinalp NM, Ozcebe OI, Ozdemir O, Dundar SV, Kirazli S. Megakaryocytopoietic cytokines in autoimmune thrombocytopenic purpura. Am J Haematol 1995; 49:256265.
  • 57
    Lee JH, Wang LC, Lin YT, Yang YH, Lin DT, Chiang BL. Inverse correlation between CD4+ CD25+ T cell population and autoantibody levels in pediatric patients with systemic lupus erythematosus. Immunology 2006; 117:280286.
  • 58
    Hori S, Carvalho TL, Demengeot J. CD4+ CD25+ regulatory T cells suppress CD4+ cell-mediated pulmonary hyperinflammation driven by Pneumocytstis carinii in immunodeficient mice. Eur J Immunol 2002; 32:12821291.
  • 59
    Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor foxp3. Science 2003; 299:10571061.
  • 60
    Chen W, Wahl SM. TGF-beta: the missing link in CD4+ CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 2003; 14:8590.
  • 61
    Ehrenstein MR, Evans JG, Singh A et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy. J Exp Med 2004; 200:277285.
  • 62
    Stasi R, Cooper N, Del Poeta G et al. Analysis of regulatory T-cell changes in patients with idiopthic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008; 112:11471150.
  • 63
    Ling Y, Cao XS, Yu ZQ et al. Alterations of CD4+ CD25+ regulatory T cells in patients with idiopathic thrombocytopenic purpura. Zhonghua Xue Ye Xue Za Zhi 2007; 28:184188.
  • 64
    Shu MM, Cao XM, Zhang WG. Role of CD4+ CD25high T cells in the pathogenesis of idiopathic thrombocytopenic purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008; 16:875877.
  • 65
    Mazzucco KL, Junior LM, Lemos NE et al. Assessment of regulatory T cells in childhood immune thrombocytopenic purpura. ISRN Hematol 2013; 5:143687.
  • 66
    Semple JW. T cell and cytokine abnormalities in patients with autoimmune thrombocytopenic purpura. Transfus Apher Sci 2003; 28:237242.
  • 67
    Wang T, Zhao H, Ren H et al. Type 1 and Type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Hematol J 2005; 90:914923.
  • 68
    Webber NP, Mascarenhas JO, Crow MK, Bussel J, Schattner EJ. Functional properties of lymphocytes in idiopathic thrombocytopenic purpura. Hum Immunol 2001; 62:13461355.
  • 69
    Andersson J. Cytokines in idiopathic thrombocytopenic purpura (ITP). Acta Paediatr Suppl 1998; 424:6164.
  • 70
    La Cava A. Tregs are regulated by cytokines: implications for autoimmunity. Autoimmun Rev 2008; 8:8387.
  • 71
    Rocha AM, Souza C, Rocha GA et al. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica 2011; 96:15601564.
  • 72
    Wang JD, Chang TK, Lin HK, Huang FL, Wang CJ, Lee HJ. Reduced expression of transforming growth factor-β1 and correlated elevation of interleukin-17 and interferon-γ in pediatric patients with chronic primary immune thrombocytopenia (ITP). Pediatr Blood Cancer 2011; 57:636640.
  • 73
    Del Vecchio GC, Giordano P, Tesse R, Piacente L, Altomare M, De Mattia D. Clinical significance of serum cytokine levels and thrombopoietic markers in childhood idiopathic thrombocytopenic purpura. Blood Transfus 2012; 10:194199.
  • 74
    Zhou B, Zhao H, Yang RC, Han ZC. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol 2005; 54:107116.
  • 75
    Munschauer FE, Hartrich LA, Stewart CC, Jacobs L. Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J Neuroimmunol 1995; 62:177181.